NCT04600778
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Cavosonstat Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Phase: Phase 2
Role: Lead Sponsor
Start: Feb 3, 2021
Completion: Apr 30, 2022